
Sign up to save your podcasts
Or


🎙️ Real Pharma – Episode Title: Breaking the Silence: Why Pharma Needs to Speak Up
In this episode of Real Pharma, Na-Ri and Ian sit down with Brian Reid—a healthcare communicator, strategist, and former journalist who's worked across government, pharma, and media—to explore a provocative question: Why is the pharmaceutical industry so quiet when it comes to telling its own story?
Together, they unpack the communication failures shaping drug pricing, PBMs, the Inflation Reduction Act (IRA), biosimilars, and the broader healthcare system. Brian argues that the problem isn’t a lack of data or platforms—it’s a lack of courage, clarity, and commitment to narrative.
From the importance of speaking up in a noisy media environment to the myth of reputational risk, this conversation is a must-listen for anyone in life sciences, policy, or healthcare storytelling.
Why pharma’s “default to silence” is damaging public trust—and what the industry can do instead
The communications trap around complex topics like PBMs, pricing, and benefit design
How public perception problems could have been avoided with smarter storytelling (hello, Hep C)
Why simplicity is power—and how “pharm-to-table” and Mark Cuban are reframing the narrative
The case for overcommunication in the face of misinformation and AI-driven “slop”
Why the Medicare Prescription Payment Plan was a missed communication opportunity—and how to fix it
“We're in a 30-year experiment of what happens when pharma steps back from the policy debate—and the results are in.” – Brian Reid
“I just want pharma to beat Bigfoot in public trust. That’s my goal.” – Brian Reid
“When in doubt, just shout. Say something. Do something.” – Na-Ri Oh
“It’s not always about having the perfect message—it’s about showing up and making the case.” – Ian Wendt
Cost Curve – Brian Reid’s daily newsletter on healthcare policy: ReidStrategic.com
KFF’s piece on complexity as a barrier to affordability
Examples from Mark Cuban’s Cost Plus Drugs and Eli Lilly CEO Dave Ricks’ public podcast appearances
💼 Website: ReidStrategic.com
📬 Newsletter: Cost Curve
💬 LinkedIn: Brian Reid
By RealPharma5
1212 ratings
🎙️ Real Pharma – Episode Title: Breaking the Silence: Why Pharma Needs to Speak Up
In this episode of Real Pharma, Na-Ri and Ian sit down with Brian Reid—a healthcare communicator, strategist, and former journalist who's worked across government, pharma, and media—to explore a provocative question: Why is the pharmaceutical industry so quiet when it comes to telling its own story?
Together, they unpack the communication failures shaping drug pricing, PBMs, the Inflation Reduction Act (IRA), biosimilars, and the broader healthcare system. Brian argues that the problem isn’t a lack of data or platforms—it’s a lack of courage, clarity, and commitment to narrative.
From the importance of speaking up in a noisy media environment to the myth of reputational risk, this conversation is a must-listen for anyone in life sciences, policy, or healthcare storytelling.
Why pharma’s “default to silence” is damaging public trust—and what the industry can do instead
The communications trap around complex topics like PBMs, pricing, and benefit design
How public perception problems could have been avoided with smarter storytelling (hello, Hep C)
Why simplicity is power—and how “pharm-to-table” and Mark Cuban are reframing the narrative
The case for overcommunication in the face of misinformation and AI-driven “slop”
Why the Medicare Prescription Payment Plan was a missed communication opportunity—and how to fix it
“We're in a 30-year experiment of what happens when pharma steps back from the policy debate—and the results are in.” – Brian Reid
“I just want pharma to beat Bigfoot in public trust. That’s my goal.” – Brian Reid
“When in doubt, just shout. Say something. Do something.” – Na-Ri Oh
“It’s not always about having the perfect message—it’s about showing up and making the case.” – Ian Wendt
Cost Curve – Brian Reid’s daily newsletter on healthcare policy: ReidStrategic.com
KFF’s piece on complexity as a barrier to affordability
Examples from Mark Cuban’s Cost Plus Drugs and Eli Lilly CEO Dave Ricks’ public podcast appearances
💼 Website: ReidStrategic.com
📬 Newsletter: Cost Curve
💬 LinkedIn: Brian Reid

38,915 Listeners

25,799 Listeners

4,362 Listeners

154 Listeners

112,275 Listeners

1,427 Listeners

9,079 Listeners

339 Listeners

232 Listeners

6,082 Listeners

10,194 Listeners

35 Listeners

760 Listeners

58,230 Listeners

5,541 Listeners